Effect of sodium butyrate on pro-matrix metalloproteinase-9 and -2 differential secretion in pediatric tumors and cell lines

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 3, 2005, Pages 463-473

  Rodriguez Salvador J ^a   Armas Pineda, C ^a   Perezpena Diazconti M ^a   Chico Ponce De Leon F ^a   Sosa Sainz G ^a   Lezama, P ^a   Recillas Targa, F ^b   Arenas Huertero, Francisco ^b  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Astrocytoma; Chromatin; Histone H4; MMPs; Sodium butyrate

Indexed keywords

BUTYRIC ACID; GELATIN; GELATINASE A; GELATINASE B; HISTONE H4; PROTEINASE;

ACETYLATION; ARTICLE; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME RELEASE; EPIGENETICS; FIBROSARCOMA; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SOLID TUMOR; ZYMOGRAPHY;

ACETYLATION; BUTYRIC ACID; CELL LINE, TUMOR; CHILD; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME PRECURSORS; HISTONES; HUMANS; HYDROLYSIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASMS;

EID: 26244457666     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Johnstone R.W.: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. 1: 287-299, 2002.
2. Peterson C.L., Logic C.: Recruitment of chromatin remodeling machines. J. Cell. Biochem. 78: 179-185, 2000.
3. Arenas-Huertero F., Recillas-Targa F.: Modificaciones epigeneticas de la cromatina en la generacion de cancer. Gac. Méd. Méx. 138: 547-555, 2002.
4. Cairos B.R.: Emerging roles for chromatin remodeling in cancer biology. Trends Cell Biol. 11: S15-S21, 2001.
5. Moggs J.G., Goodman J.I., Trosko J.E., Roberts R.A.: Epigenetics and cancer: implications for drug discovery and safety assessment. Tox. Appl. Pharmacol. 196: 422-430, 2004.
6. Hake S.B., Allis C.D.: Linking the epigenetic "language" of covalent histone modifications to cancer. Br. J. Cancer. 90: 761-769, 2004.
7. Narlikar G.J., Fan H.Y., Kingston R.E.: Cooperation between complexes that regulate chromatin structure and transcription. Cell 108: 475-487, 2002.
8. Davie J.R., Spencer V.A.: Control of histone modifications. J. Cell Biochem. Suppl. 32/33: 141-148, 1999.
9. Roth S.Y., Denu J.M., Allis C.D.: Histone acetyltransferases. Annu. Rev. Biochem. 70: 81-120, 2001.
10. Marks P.A., Miller T., Richon V.M.: Histone deacetylases. Curr. Op. Pharmacol. 3: 344-351, 2003.
11. Davis P.K., Brackmann R.K.: Chromatin remodeling and cancer. Cancer Biol. Ther. 2: 22-29, 2003.
12. Feinberg A.P., Tycko B.: The history of cancer epigenetics. Nature Rev. Cancer. 4: 143-153, 2004.
13. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K.: Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1: 194-202, 2001.
14. Warrel R.P., He L.Z., Richon V., Calleja E., Pandolfi P.P.: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 90: 1621-1625, 1998.
15. Fenrick R., Hiebert S.W.: Role of histone deacetylases in acute leukemia. J. Cell Biochem. 31 (Suppl.): 194-202, 1998.
16. Egeblad M., Web Z.: New functions for the matrix metallopro-teinases in cancer progression. Nat. Rev. Cancer. 2: 161-174, 2002.
17. Coussens L.M., Werb Z.: Matrix metalloproteinases and the development of cancer. Chem. Biol. 3: 895-904, 1996.
18. Stamenkovic I.: Extracellular matrix remodeling: the role of matrix metalloproteinases. J. Pathol. 200: 448-464, 2003.
19. Yoon S.O., Park S.J., Yun Ch.H., Chung A.S.: Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J. Biochem. Mol. Biol. 1: 128-137, 2003.
20. Ailenberg M., Silverman M.: Trichostatin A -histone deacetylase inhibitor with clinical therapeutic potential- is also a selective and potent inhibitor of gelatinase A expression. Biochem. Biophys. Res. Comm. 298: 110-115, 2002.
21. Yan Ch., Wang H., Toh Y., Boyd D.G.: Repression of 92 kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation. J. Biol. Chem. 278: 2309-2316, 2003.
22. Arenas-Huertero F.J., Delgado-Chavez R., Herrera-Goepfert R., Zinser-Sierra J.W., Herrera-Gomez A., Perez-Cardenas E.: Matrix- metalloproteinases expressed in squamous cell carcinoma of the oral cavity. Correlation with clinicopathological features and neoadjuvant chemotherapy response. J. Exp. Clin. Cancer. Res. 18: 279-284, 1999.
23. Yoshida M., Kijima M., Akita M., Beppu T.: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265: 17174-17179, 1990.
24. Sato N., Maehara N., Su G. H., Goggins M.: Effects of 5-Aza-2′-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J. Natl. Cancer Inst. 95: 327-330, 2003.
25. Chicoine E., Esteve P-O., Robledo O., Van Themsche C., Potworowski E.F., St-Pierre Y.: Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem. Biophys. Res. Comm. 297: 765-772, 2002.
26. Mc Laughlin F., Finn P., La Thangue N.B.: The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. Drug Disc. Today 8: 793-802, 2003.
27. Gilbert J.: A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid malignancies. Clin. Cancer Res. 7: 2292-2300, 2001.